Several miRNAs, including miR-362-5p, miR-501-5p and miR-922, have been described to be Cyld-negative regulators in HCC [66,67,68], and miR-182-mediated Cyld regulation has been demonstrated in glioma [69] and in gastrointestinal stromal tumors [70], highlighting the possible role of a specific antagomir as a promising therapeutic strategy [71,72]. This evidence concerns the gene CYLD and central nervous system cancer.